[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633332":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":55,"collaborators":26,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":26,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":26,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":80,"whyStopped":26,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University of Nove de Julho","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Photobiomodulation","EXPERIMENTAL","Participants will receive vascular photobiomodulation therapy applied over the radial artery using a red laser (wavelength: 660 nm; power: 100 mW). Each session will last 30 minutes, with a total energy delivery of 180 J per session. Sessions will be performed twice per week for 4 weeks.",[13],"Device: Vascular Photobiomodulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham Photobiomodulation","SHAM_COMPARATOR","Participants will undergo an identical procedure to the experimental group; however, the laser emission will be blocked to ensure no therapeutic effect. All procedures, duration, and frequency will be identical to the experimental group to maintain blinding.",[19],"Device: Sham Photobiomodulation",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Vascular Photobiomodulation","Vascular photobiomodulation therapy applied over the radial artery using a red laser (wavelength: 660 nm; power: 100 mW).",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Laser emission will be blocked to ensure no therapeutic effect",[15],[31],{"name":32,"affiliation":5,"role":33},"Raphael Dias, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":26,"email":39},"Celso Muniz, MD","CONTACT","+55 11 98369-6696","freitas_celso@uol.com.br",[41],{"facility":42,"status":26,"city":43,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Raphael Dias","São Paulo","01525-000","Brazil","BR",{"type":48,"coordinates":49},"Point",[50,51],-46.63611,-23.5475,{"lat":51,"lon":50},[54],{"name":36,"role":37,"phone":38,"phoneExt":26,"email":39},{"type":33,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Raphael Mendes Ritti Dias","Professor","100633332","photobiomodulation-effects-on-blood-pressure-and-vascular-function-in-treated-hypertensive-patients-100633332",false,"NCT07525310","Photobiomodulation Effects on Blood Pressure and Vascular Function in Treated Hypertensive Patients","Effect of Vascular Photobiomodulation on Cardiovascular Parameters of Treated Hypertensive Patients: A Randomized and Controlled Clinical Trial","Inclusion Criteria:\n\n* Patient in use of losartan at a dose of 100 mg\u002Fday divided into two doses as the only antihypertensive medication, for a minimum of 2 months.\n* Present systolic blood pressure is less than or equal to 140 mmHg and diastolic less than or equal to 90 mmHg.\n* Not having used any other antihypertensive medication in the last 2 months.\n* Age between 18 and 65 years\n* If female, not pregnant\n* No cutaneous\u002Fsubcutaneous lesions on both arms.\n* No musculoskeletal, rheumatic, cardiovascular, metabolic, neurological, oncological, immunological, hematological, psychiatric or cognitive diagnoses and that may be worsened by the intervention or prevent the correct application of FBM vascular.\n\nExclusion Criteria:\n\n* Changes in medication status during the study","ALL","18 Years","65 Years",{"count":69,"type":70},80,"ESTIMATED","INTERVENTIONAL",[73],"NA","This double-blind, randomized, sham-controlled clinical trial aims to evaluate the effects of vascular photobiomodulation on blood pressure and vascular function in hypertensive patients treated with losartan. A total of 80 patients using losartan (100 mg\u002Fday for at least two months) will be recruited and followed for 4 weeks. Participants will be randomly allocated to either an active photobiomodulation group or a sham control group.",[76],"Hypertension",[23,78,79],"Blood pressure","Vascular function","NOT_YET_RECRUITING","2026-04-06",{"date":83,"type":84},"2026-04-13","ACTUAL",{"date":86,"type":70},"2026-05-01",{"date":88,"type":70},"2027-11-30",{"name":5,"class":6},1]